Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma.
BACKGROUND/AIM To determine if overexpression of the glaucoma gene MYOC is involved in the development of open-angle glaucoma (OAG) and if its promoter variants are associated with glaucoma in the Korean population. METHODS Human trabecular meshwork cells were cultured in the presence of ophthalmic steroids such as fluorometholone, fluorometholone acetate, dexamethasone, prednisolone acetate and rimexolone. The cells were cultured at a hydrostatic pressure of 32 mm Hg above atmospheric pressure and induction of MYOC was evaluated by northern blot analysis. Genomic DNA was extracted from blood samples obtained from 74 normal controls and 168 unrelated Korean patients with OAG, including primary OAG, normal tension glaucoma and steroid-induced glaucoma. A 461 base pair (bp) DNA fragment of the MYOC promoter region was amplified using PCR and its genotype was analysed by directly sequencing the product. RESULTS The potencies of steroid eye drops in MYOC induction in vitro was the same regardless of their potential for elevating intraocular pressure in vivo. Hydrostatic pressure had no effect on MYOC induction. A dinucleotide repeat polymorphism and three single nucleotide polymorphisms were identified, but no obvious differences in the genotype distribution and allele frequency of the variants between the control group and any type of OAG were observed. CONCLUSION Our data suggest that MYOC overexpression is not a cause or an effect of intraocular pressure elevation and that MYOC itself is not associated with OAG.
Sohn
Seongsoo
S
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea.
Hur
Wonhee
W
Choi
Young Ran
YR
Chung
Yun Shin
YS
Ki
Chang-Seok
CS
Kee
Changwon
C
D002478:Cells, Cultured; D003598:Cytoskeletal Proteins / Q000235:genetics* / Q000378:metabolism; D005136:Eye Proteins / Q000235:genetics* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005902:Glaucoma, Open-Angle / Q000235:genetics*; D005938:Glucocorticoids / Q000494:pharmacology; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D006874:Hydrostatic Pressure; D020641:Polymorphism, Single Nucleotide; D014129:Trabecular Meshwork / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000099179:Myocilin
D003598:Cytoskeletal Proteins; D005136:Eye Proteins; D005938:Glucocorticoids; D006023:Glycoproteins; D000099179:Myocilin
Arch Ophthalmol. 2001 Nov;119(11):1674-8
11709019
Invest Ophthalmol Vis Sci. 1998 Mar;39(3):517-25
9501861
J Glaucoma. 2004 Oct;13(5):377-84
15354075
Ophthalmic Res. 2005 Sep-Oct;37(5):235-42
16020952
Br J Ophthalmol. 2000 Sep;84(9):1078
11032443
Clin Genet. 2003 Jul;64(1):18-27
12791035
Arch Ophthalmol. 1996 Aug;114(8):933-7
8694727
Mol Vis. 2007 Jun 14;13:862-72
17615537
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):145-52
11133859
Acta Ophthalmol Scand. 2002 Aug;80(4):384-6
12190780
Mol Cell Biol. 2001 Nov;21(22):7707-13
11604506
Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3165-72
11726618
Arch Ophthalmol. 2002 Sep;120(9):1189-97
12215093
Mol Cell Biol. 2004 Oct;24(20):9019-25
15456875
Eur J Hum Genet. 2005 Mar;13(3):384-7
15483649
Arch Ophthalmol. 1980 Sep;98(9):1577-8
6893544
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):33-40
11773009
Clin Genet. 2001 Sep;60(3):220-5
11595024
Science. 1997 Jan 31;275(5300):668-70
9005853
Mol Vis. 2005 Nov 02;11:916-21
16280977
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1724-9
10845592
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4163-8
11095610
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):223-34
15623777
J Biol Chem. 1998 Mar 13;273(11):6341-50
9497363
Ann Ocul (Paris). 1954 Sep;187(9):805-16
13218439